Antiviral therapies play a crucial role in managing viral infections by targeting specific viruses to inhibit their replication and spread within the body. These therapies can vary widely depending on the virus being targeted and may include medications such as nucleoside analogs, protease inhibitors, and neuraminidase inhibitors. Nucleoside analogs, for example, work by interfering with viral DNA or RNA synthesis, thereby preventing the virus from replicating. Protease inhibitors, on the other hand, block the activity of viral proteases, essential enzymes required for viral replication. Neuraminidase inhibitors are commonly used to treat influenza viruses by inhibiting the activity of neuraminidase, an enzyme necessary for viral release from infected cells. While antiviral therapies can effectively reduce the severity and duration of viral infections, they may also be associated with side effects and the development of drug-resistant strains, highlighting the importance of ongoing research and development in this field.
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Pathogen-derived noncanonical epitopes: Are they valuable targets for novel vaccinations and shall we be concerned about autoimmune responses?
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : When acute EBV mimics HIV: A case of false positive p24 antigen and low-level HIV antibody reactivity
Smriti Chaudhary, Imperial College Healthcare NHS Trust, United Kingdom
Title : OnePeru: Peruvian bioinformatics platform to contribute to the fight against antimicrobial resistance
Pool Marcos Carbajal, University of San Martin de Porres, Peru
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain